We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
Read MoreHide Full Article
NRx Pharmaceuticals (NRXP - Free Report) is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed product, the company is not likely to have generated revenues in the to-be-reported quarter.
In the past 60 days, the Zacks Consensus Estimate for NRx Pharmaceuticals’ 2024 loss per share has remained constant at $1.75. During the same time frame, the company’s 2025 loss per share forecast has remained constant at 8 cents.
Image Source: Zacks Investment Research
NRXP Earnings Surprise History
NRx Pharmaceuticals’ performance has been encouraging over the trailing three quarters, with earnings beating estimates in each of the quarters. On average, NRXP registered an earnings surprise of 39.15% in the last three quarters. In the last reported quarter, the company reported an earnings surprise of 81.48%.
Image Source: Zacks Investment Research
Earnings Whispers for NRXP
Our proven model does not conclusively predict an earnings beat for NRx Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
In the absence of a marketed product in its commercial portfolio, the company is likely to provide a thorough update on its novel pipeline candidates, which are being developed for treating central nervous system disorders, specifically suicidal bipolar depression, chronic pain, post-traumatic stress disorder (“PTSD”) and schizophrenia.
The company has two lead drug candidates – NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone, and NRX-100, a preservative-free formulation of ketamine for intravenous (IV) infusion.
NRX-101 is being developed in a phase IIb/III study for the treatment of suicidal bipolar depression, chronic pain and PTSD, while IV ketamine (NRX-100) is being developed for the treatment of suicidal depression.
In December 2024, NRx Pharmaceuticals submitted the initial section of the new drug application (“NDA”) to the FDA for NRX-100 (IV ketamine) for the treatment of suicidal depression, which is considered a national crisis.
While assembly of the clinical data is being completed, the FDA has asked NRXP to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review before submitting the final efficacy data and other sections, which is expected in the first quarter of 2025.
If approved, NRX-100 would be the first medicine to treat acute suicidality in the world.
The company is expected to have provided updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call.
Research and development expenses are expected to have decreased in the to-be-reported quarter, due to the conclusion of the phase IIb/III study on NRX-101.
NRXP's Price Performance
The stock has rallied 86.1% in the past three months against the industry’s 5.4% decline. NRXP has also outperformed the S&P 500 and the sector in the same period, as seen in the chart below. NRx Pharmaceuticals is currently trading above the 200-day moving average and below the 50-day moving average.
NRXP Stock Outperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Investment Thesis
NRx Pharmaceuticals is still a clinical-stage company engaged in drug discovery and development, which has historically been complex, costly and prone to failure. Traditional biotech companies rely on a “trial-and-error” approach, leading to significant cash burn during early research and development. The high failure rates and funding challenges often result in financial instability, hindering progress in the sector.
The successful development and approval of its candidates would significantly enhance shareholder value in the long run.
NRx Pharmaceuticals’ wholly owned subsidiary, HOPE Therapeutics, aims to offer a network of precision psychiatry clinics to study precision psychiatric treatment. Per management, IV ketamine has now become a standard of care for the acute treatment of suicidal depression in the absence of an FDA-labeled product.
Competition in the target market remains a worry for NRx Pharmaceuticals as several companies are also engaged in developing treatments for schizophrenia and bipolar I disorder.
Though J&J’s (JNJ - Free Report) Spravato (esketamine) is approved by the FDA for treatment-resistant depression, it has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression.
Meanwhile, Alkermes’ (ALKS - Free Report) Lybalvi (olanzapine and samidorphan) is approved by the FDA for the treatment of adults with schizophrenia and adults who have bipolar I disorder. It is approved as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.
With clinical studies progressing well, existing investors should hold NRXP stock for long-term gains, no matter how fourth-quarter results pan out.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
NRx Pharmaceuticals (NRXP - Free Report) is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed product, the company is not likely to have generated revenues in the to-be-reported quarter.
See the Zacks Earnings Calendar to stay ahead of market-making news.
In the past 60 days, the Zacks Consensus Estimate for NRx Pharmaceuticals’ 2024 loss per share has remained constant at $1.75. During the same time frame, the company’s 2025 loss per share forecast has remained constant at 8 cents.
Image Source: Zacks Investment Research
NRXP Earnings Surprise History
NRx Pharmaceuticals’ performance has been encouraging over the trailing three quarters, with earnings beating estimates in each of the quarters. On average, NRXP registered an earnings surprise of 39.15% in the last three quarters. In the last reported quarter, the company reported an earnings surprise of 81.48%.
Image Source: Zacks Investment Research
Earnings Whispers for NRXP
Our proven model does not conclusively predict an earnings beat for NRx Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
NRx Pharmaceuticals has an Earnings ESP of -0.20% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Factors Shaping NRXP's Upcoming Results
In the absence of a marketed product in its commercial portfolio, the company is likely to provide a thorough update on its novel pipeline candidates, which are being developed for treating central nervous system disorders, specifically suicidal bipolar depression, chronic pain, post-traumatic stress disorder (“PTSD”) and schizophrenia.
The company has two lead drug candidates – NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone, and NRX-100, a preservative-free formulation of ketamine for intravenous (IV) infusion.
NRX-101 is being developed in a phase IIb/III study for the treatment of suicidal bipolar depression, chronic pain and PTSD, while IV ketamine (NRX-100) is being developed for the treatment of suicidal depression.
In December 2024, NRx Pharmaceuticals submitted the initial section of the new drug application (“NDA”) to the FDA for NRX-100 (IV ketamine) for the treatment of suicidal depression, which is considered a national crisis.
While assembly of the clinical data is being completed, the FDA has asked NRXP to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review before submitting the final efficacy data and other sections, which is expected in the first quarter of 2025.
If approved, NRX-100 would be the first medicine to treat acute suicidality in the world.
The company is expected to have provided updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call.
Research and development expenses are expected to have decreased in the to-be-reported quarter, due to the conclusion of the phase IIb/III study on NRX-101.
NRXP's Price Performance
The stock has rallied 86.1% in the past three months against the industry’s 5.4% decline. NRXP has also outperformed the S&P 500 and the sector in the same period, as seen in the chart below. NRx Pharmaceuticals is currently trading above the 200-day moving average and below the 50-day moving average.
NRXP Stock Outperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Investment Thesis
NRx Pharmaceuticals is still a clinical-stage company engaged in drug discovery and development, which has historically been complex, costly and prone to failure. Traditional biotech companies rely on a “trial-and-error” approach, leading to significant cash burn during early research and development. The high failure rates and funding challenges often result in financial instability, hindering progress in the sector.
The successful development and approval of its candidates would significantly enhance shareholder value in the long run.
NRx Pharmaceuticals’ wholly owned subsidiary, HOPE Therapeutics, aims to offer a network of precision psychiatry clinics to study precision psychiatric treatment. Per management, IV ketamine has now become a standard of care for the acute treatment of suicidal depression in the absence of an FDA-labeled product.
Competition in the target market remains a worry for NRx Pharmaceuticals as several companies are also engaged in developing treatments for schizophrenia and bipolar I disorder.
Though J&J’s (JNJ - Free Report) Spravato (esketamine) is approved by the FDA for treatment-resistant depression, it has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression.
Meanwhile, Alkermes’ (ALKS - Free Report) Lybalvi (olanzapine and samidorphan) is approved by the FDA for the treatment of adults with schizophrenia and adults who have bipolar I disorder. It is approved as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.
With clinical studies progressing well, existing investors should hold NRXP stock for long-term gains, no matter how fourth-quarter results pan out.